title: Mapping of the sites responsible for factor I-cofactor activity for cleavage of C3b and C4b on human C4b-binding protein (C4bp) by deletion mutagenesis.
abstract: Human C4b-binding protein (C4bp) facilitates the factor I-mediated proteolytic cleavage of the active forms of complement effectors C3b and C4b into their inactive forms. C4bp comprises a disulfide-linked heptamer of alpha-chains with complement (C) regulatory activity and a beta-chain. Each alpha-chain contains 8 short consensus repeat (SCR) domains. Using SCR-deletion mutants of recombinant multimeric C4bp, we identified the domains responsible for the C3b/C4b-binding and C3b/C4b-inactivating cofactor activity. The C4bp mutant with deletion of SCR2 lost the C4b-binding ability, as judged on C3b/C4b-Sepharose binding assaying and ELISA. In contrast, the essential domains for C3b-binding extended more to the C-terminus, exceeding SCR4. Using fluid phase cofactor assaying and deletion mutants of C4bp, SCR2 and 3 were found to be indispensable for C4b cleavage by factor I, and SCR1 contributed to full expression of the factor I-mediated C4b cleaving activity. On the other hand, SCR1, 2, 3, 4, and 5 participated in the factor I-cofactor activity for C3b cleavage, and SCR2, 3, and 4 were absolutely required for C3b inactivation. Thus, different sets of SCRs participate in C3b and C4b inactivation, and the domain repertoire supporting C3b cofactor activity is broader than that supporting C4b inactivation by C4bp and factor I. Furthermore, the domains participating in C3b/C4b binding are not always identical to those responsible for cofactor activity. The necessity of the wide range of SCRs in C3b inactivation compared to C4b inactivation by C4bp and factor I may reflect the physiological properties of C4bp, which is mainly directed to C4b rather than C3b.
authors.affiliation: Department of Pharmaceutical Sciences, Hokkaido University, Kita-ku, Sapporo 060.
authors.forename: Aya
authors.initials: A
authors.lastname: Fukui
authors.forename: Tomoko
authors.initials: T
authors.lastname: Yuasa-Nakagawa
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Murakami
authors.forename: Kenji
authors.initials: K
authors.lastname: Funami
authors.forename: Natue
authors.initials: N
authors.lastname: Kishi
authors.forename: Tadashi
authors.initials: T
authors.lastname: Matsuda
authors.forename: Teizo
authors.initials: T
authors.lastname: Fujita
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Seya
authors.forename: Shigeharu
authors.initials: S
authors.lastname: Nagasawa
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D001798:Blood Proteins / Q000378:metabolism; D020134:Catalytic Domain; D003179:Complement C3b / Q000378:metabolism*; D003180:Complement C3b Inactivator Proteins; D015935:Complement C4b / Q000378:metabolism*; D017244:Complement Factor I / Q000378:metabolism*; D003169:Complement Inactivator Proteins / Q000235:genetics* / Q000276:immunology / Q000378:metabolism; D006023:Glycoproteins; D006801:Humans; D017384:Sequence Deletion
chemical_list: D000911:Antibodies, Monoclonal; D001798:Blood Proteins; D003180:Complement C3b Inactivator Proteins; D003169:Complement Inactivator Proteins; D006023:Glycoproteins; D003179:Complement C3b; D015935:Complement C4b; D017244:Complement Factor I